Fig. 2: HR according to biomarkers analysis. | Nature Communications

Fig. 2: HR according to biomarkers analysis.

From: Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

Fig. 2: HR according to biomarkers analysis.

Forest plot representing HR for Overall Survival according to Jak mutations, IFN gamma expression and TMB in Arm A (targeted therapy followed by immunotherapy), Arm B (immunotherapy followed by targeted therapy), and Arm C (a course of targeted therapy preceding immunotherapy and targeted therapy) of SECOMBIT. Source data are provided as a Source Data file.

Back to article page